Loading...
KRAS mutant tumor subpopulations can subvert durable responses to personalized cancer treatments
KRAS mutations in colorectal and lung cancers predict failure to respond to therapies that target the EGFR. Significant percentages of patients with KRAS wild-type tumors also fail to respond to these therapies. Relapse occurs in patients with KRAS wild-type and mutant tumors, with moderately longer...
Na minha lista:
| Udgivet i: | Per Med |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2013
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5115778/ https://ncbi.nlm.nih.gov/pubmed/27867401 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/pme.13.1 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|